Assembly Biosciences, Inc.

Healthcare · Biotechnology · United States

Last price 20.13 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 409.86M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next g...